Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

Pierre Fumoleau, Jose Manuel Trigo, Nicolas Isambert, Dorothée Sémiond, Sunil Gupta, Mario Campone, Pierre Fumoleau, Jose Manuel Trigo, Nicolas Isambert, Dorothée Sémiond, Sunil Gupta, Mario Campone

Abstract

Background: Cabazitaxel is approved in patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-containing regimen. This study evaluated a weekly cabazitaxel dosing regimen. Primary objectives were to report dose-limiting toxicities (DLTs) and to determine the maximum tolerated dose (MTD). Efficacy, safety and pharmacokinetics were secondary objectives.

Methods: Cabazitaxel was administered weekly (1-hour intravenous infusion at 1.5-12 mg/m² doses) for the first 4 weeks of a 5-week cycle in patients with solid tumours. Monitoring of DLTs was used to determine the MTD and the recommended weekly dose.

Results: Thirty-one patients were enrolled. Two of six patients experienced DLTs at 12 mg/m², which was declared the MTD. Gastrointestinal disorders were the most common adverse event. Eight patients developed neutropenia (three ≥ Grade 3); one occurrence of febrile neutropenia was reported. There were two partial responses (in breast cancer) and 13 patients had stable disease (median duration of 3.3 months). Increases in C(max) and AUC(0-t) were dose proportional for the 6-12 mg/m² doses.

Conclusion: The MTD of weekly cabazitaxel was 12 mg/m² and the recommended weekly dose was 10 mg/m². The observed safety profile and antitumour activity of cabazitaxel were consistent with those observed with other taxanes in similar dosing regimens.

Trial registration: The study was registered with ClinicalTrials.gov as NCT01755390.

Figures

Figure 1
Figure 1
Cabazitaxel pharmacokinetics. (a) Cmax versus dose and (b) AUC0–t versus dose at the first administration at cycle 1 (n = 21).

References

    1. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 1994;344:1267–1272. doi: 10.1016/S0140-6736(94)90754-4.
    1. Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. Chem Med Chem. 2007;2:920–942.
    1. Bissery M-C, Bouchard H, Riou JF, Vrignaud P, Combeau J, Bourzat JD. et al.Preclinical evaluation of TXD258, a new taxoid [abstract #1364] Proc Am Assoc Cancer Res. 2000;41:214.
    1. Attard G, Greystoke A, Kaye S, de Bono J. Update on tubulin-binding agents. Pathol Biol (Paris) 2006;54:72–84. doi: 10.1016/j.patbio.2005.03.003.
    1. Vrignaud P, Lejeune P, Chaplin D, Lavelle F, Bissery M-C. In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts [abstract #1365] Proc Am Assoc Cancer Res. 2000;41:214.
    1. Vrignaud P, Lejeune P, Bissery M-C. TXD258, a new taxoid, with oral antitumor activity [abstract #1975] Proc Am Assoc Cancer Res. 2001;41:214.
    1. Dykes DJ, Sarsat JP, Bissery M-C. Efficacy evaluation of TXD258, a taxoid compound, against orthotopic and subcutaneous glioblastomas [abstract #1916] Proc Am Assoc Cancer Res. 2000;41:301.
    1. Dieras V, Lortholary A, Laurence V, Delva R, Girre V, Livartowski A. et al.Cabazitaxel in patients with advanced solid tumours: results of a phase I and pharmacokinetic study. Eur J Cancer. 2013;49:25–34. doi: 10.1016/j.ejca.2012.07.008.
    1. Mita AC, Denis LJ, Rowinsky EK, de Bono JS, Goetz AD, Ochoa L. et al.Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723–730. doi: 10.1158/1078-0432.CCR-08-0596.
    1. Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G. et al.A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19:1547–1552. doi: 10.1093/annonc/mdn171.
    1. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I. et al.Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154. doi: 10.1016/S0140-6736(10)61389-X.
    1. Sanofi. JEVTANA® (cabazitaxel) Injection, Summary of Product Characteristics. Paris, France; 2013. Available at: .
    1. Sanofi U.S. LLC. JEVTANA® (cabazitaxel) Injection, Prescribing Information. Bridgewater NJ, USA;; 2013. Available at: HYPERLINK .
    1. Simon P, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997;89:1138–1147. doi: 10.1093/jnci/89.15.1138.
    1. U.S. Department of Health and Human Services, National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0. 1999.
    1. Ferron GM, Dai Y, Sémiond D. Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71:681–692. doi: 10.1007/s00280-012-2058-9.
    1. Aller AW, Kraus LA, Bissery M-C. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines [abstract #1923] Proc Am Assoc Cancer Res. 2000;41:303.
    1. Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvert L, Combeau C. et al.Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res. 2013;19:2973–2983. doi: 10.1158/1078-0432.CCR-12-3146.
    1. Ozguroglu M, Oudard S, Sartor AO, Hansen S, Machiels JP, Shen L. et al.Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study. J Clin Oncol. 2011;29:Abstract 144.
    1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzansa A, Chi KN. et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512. doi: 10.1056/NEJMoa040720.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi